Cue Biopharma (CUE) Stock Statistics & Valuation Metrics

Cue Biopharma has a market cap or net worth of $64.55M. The enterprise value is $45.27M.

Cue Biopharma has 76,845,900 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cue Biopharma’s return on equity (ROE) is -2.32 and return on invested capital (ROIC) is -157.35%.

The current PE Ratio of Cue Biopharma is ―. Cue Biopharma’s PEG ratio is ―.

In the last 12 months, Cue Biopharma had revenue of 9.29M and earned -40.67M in profits. Earnings per share was -0.72.

In the last 12 months, operating cash flow was -28.14M and capital expenditures -178.00K, giving a free cash flow of -28.32M billion.

Cue Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―

Cue Biopharma upcoming earnings date is Nov 6, 2025, TBA (Confirmed).

Cue Biopharma as a current ratio of 1.84, with Debt / Equity ratio of 42.04%

In the past 12 months, Cue Biopharma has paid 0.00 in taxes.

Cue Biopharma EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -1.31.

Cue Biopharma has $27.49M in cash and marketable securities with $7.63M in debt, giving a net cash position of -$19.86M billion.

Gross margin is 64.35%, with operating margin of -446.86%, and net profit margin of -437.97%.

The average price target for Cue Biopharma is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy